Abstract：
BACKGROUND: Radiation-induced lung disease is a potentially fatal, dose-limiting toxicity commonly seen after radiotherapy of thoracic malignancies, including breast cancer.
OBJECTIVE: To evaluate and compare the early lung toxicity induced by 3D-CRT and IMRT radiotherapy treatment modalities in breast cancer female patients using biochemical, dosimetry and clinical data.
METHODS: this study included 15 normal healthy controls, 15 breast cancer patients treated with IMRT, and 15 breast cancer patients treated with 3D-CRT. One blood sample was obtained from the control group and 3 blood samples were withdrawn from cases before RT, after RT and after 3 months of RT.
RESULTS: IMRT delivered higher radiation dose to the breast tumor and lower doses to the lung as an organ at risk. There was a non-significant increase in the serum levels of IL-6 before IMRT and 3D-CRT compared with its levels in the control group. There were significant increases in serum levels of IL-6 after RT (IMRT and 3DCRT) compared with its levels before RT. There was a non-significant decrease in the serum levels of IL-6 after 3 months of RT (IMRT and 3D-CRT) compared with its serum levels immediately after RT. There was a non-significant increase in the serum levels of SP-D before RT (IMRT and 3D-CRT) compared with its levels in the control group. There were significant-increases in serum levels of SP-D after RT (IMRT and 3D-CRT) compared with its levels before RT. There was a non-significant decrease in the serum levels of SP-D after 3 months of radiotherapy (IMRT and 3D-CRT) compared with its serum levels immediately after RT.
CONCLUSIONS: serum of levels IL-6 and SP-D can be used to diagnose the occurrence of early lung toxicity due to radiotherapy and the rate of recovery from radiation pneumonitis is apparent in case of IMRT than 3D-CRT.
OBJECTIVE: To evaluate and compare the early lung toxicity induced by 3D-CRT and IMRT radiotherapy treatment modalities in breast cancer female patients using biochemical, dosimetry and clinical data.
METHODS: this study included 15 normal healthy controls, 15 breast cancer patients treated with IMRT, and 15 breast cancer patients treated with 3D-CRT. One blood sample was obtained from the control group and 3 blood samples were withdrawn from cases before RT, after RT and after 3 months of RT.
RESULTS: IMRT delivered higher radiation dose to the breast tumor and lower doses to the lung as an organ at risk. There was a non-significant increase in the serum levels of IL-6 before IMRT and 3D-CRT compared with its levels in the control group. There were significant increases in serum levels of IL-6 after RT (IMRT and 3DCRT) compared with its levels before RT. There was a non-significant decrease in the serum levels of IL-6 after 3 months of RT (IMRT and 3D-CRT) compared with its serum levels immediately after RT. There was a non-significant increase in the serum levels of SP-D before RT (IMRT and 3D-CRT) compared with its levels in the control group. There were significant-increases in serum levels of SP-D after RT (IMRT and 3D-CRT) compared with its levels before RT. There was a non-significant decrease in the serum levels of SP-D after 3 months of radiotherapy (IMRT and 3D-CRT) compared with its serum levels immediately after RT.
CONCLUSIONS: serum of levels IL-6 and SP-D can be used to diagnose the occurrence of early lung toxicity due to radiotherapy and the rate of recovery from radiation pneumonitis is apparent in case of IMRT than 3D-CRT.
摘要：
背景：放射性肺病是一种潜在的致命疾病，胸部恶性肿瘤放疗后常见的剂量限制性毒性，包括乳腺癌.
目的：使用生化技术评估和比较3D-CRT和IMRT放疗治疗方式对乳腺癌女性患者的早期肺毒性，剂量测定和临床数据。
方法：本研究包括15名正常健康对照，15名接受IMRT治疗的乳腺癌患者，和15名接受3D-CRT治疗的乳腺癌患者。从对照组获得一份血样，从RT前的病例中抽取3份血样，RT后和RT后3个月。
结果：IMRT向乳腺肿瘤提供了较高的辐射剂量，向作为危险器官的肺提供了较低的剂量。与对照组相比，IMRT和3D-CRT前血清IL-6水平无明显升高。与RT前相比，RT后血清IL-6水平（IMRT和3DCRT）显着升高。与RT后立即的血清水平相比，RT（IMRT和3D-CRT）3个月后的IL-6血清水平无明显下降。与对照组相比，RT（IMRT和3D-CRT）前血清SP-D水平无明显升高。与RT前相比，RT（IMRT和3D-CRT）后血清SP-D水平显着升高。放疗（IMRT和3D-CRT）3个月后，SP-D的血清水平与RT后立即的血清水平相比，无明显下降。
结论：血清IL-6和SP-D水平可用于诊断放疗引起的早期肺毒性的发生，在IMRT情况下放射性肺炎的恢复率明显高于3D-CRT。
目的：使用生化技术评估和比较3D-CRT和IMRT放疗治疗方式对乳腺癌女性患者的早期肺毒性，剂量测定和临床数据。
方法：本研究包括15名正常健康对照，15名接受IMRT治疗的乳腺癌患者，和15名接受3D-CRT治疗的乳腺癌患者。从对照组获得一份血样，从RT前的病例中抽取3份血样，RT后和RT后3个月。
结果：IMRT向乳腺肿瘤提供了较高的辐射剂量，向作为危险器官的肺提供了较低的剂量。与对照组相比，IMRT和3D-CRT前血清IL-6水平无明显升高。与RT前相比，RT后血清IL-6水平（IMRT和3DCRT）显着升高。与RT后立即的血清水平相比，RT（IMRT和3D-CRT）3个月后的IL-6血清水平无明显下降。与对照组相比，RT（IMRT和3D-CRT）前血清SP-D水平无明显升高。与RT前相比，RT（IMRT和3D-CRT）后血清SP-D水平显着升高。放疗（IMRT和3D-CRT）3个月后，SP-D的血清水平与RT后立即的血清水平相比，无明显下降。
结论：血清IL-6和SP-D水平可用于诊断放疗引起的早期肺毒性的发生，在IMRT情况下放射性肺炎的恢复率明显高于3D-CRT。
